Australia
Brazil
Canada
Germany
India
Ireland
Japan
Mexico
New Zealand
Philippines
South Africa
United Kingdom
Dr. Paika Podcast
Similar topics: zepbound and glp
Health & Fitness
On The Pen GLP-1 News
by Dave Knapp GLP-1 Industry Insider
Today: #74 in Health & Fitness, Ireland on our combined chart.
Share this ranking
Claiming needs an RSS feed. Contact us.
Chart positions today · United States
Not on the United States charts we track today.
Not on the United Kingdom charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the New Zealand charts we track today.
Not on the India charts we track today.
Not on the Japan charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like On The Pen GLP-1 News, try…
Docs Who Lift
Similar topics: retatrutide and glp
A GLP-1 Guide to Metabolic Health: The Plus SideZ Podcast
Similar topics: glp and obesity
Weight & Measure
Similar topics: glp and retatrutide
The Peptide Research Podcast
Similar topics: retatrutide and peptide
This Is Your Brain On Drugs Psychiatry Podcast
Similar topics: glp and obesity
Ranking history · United States
No ranking history for this show in United States over the last 7 days.
Latest episodes
-
Eli Lilly vs. The Grey Market: The Future of Peptide Medicine
October 14, 2026 · 25 minEli Lilly’s fight over retatrutide may be about much more than one obesity drug.I’ve been covering retatrutide since early 2023, and since late 2024 I’ve been closely following the legal fight over whether reta should be treated as a…
-
Ozempic & Zepbound Are Changing America in Ways Nobody Expected
October 7, 2026 · 25 minZepbound isn’t just changing people’s weight. GLP-1 medications are beginning to change America itself. Restaurants are rethinking what they serve. Grocery baskets are changing. Food companies are paying attention to protein and portion…
-
They TRIPLED Wegovy Dose, Does it Beat Zepbound?
October 1, 2026 · 31 minThis week on On The Pen, The Weekly Dose, we break down one of the biggest weeks in obesity medicine coming out of EASD 2026.Eli Lilly says Zepbound may still outperform Wegovy 7.2 mg, even after Novo Nordisk tripled the familiar…
-
Retatrutide in Court, Compound GLP-1 Under Fire
September 22, 2026 · 30 minThis week on On The Pen, The Weekly Dose Podcast, retatrutide heads into a major federal court fight as the Department of Justice gives FDA fresh legal ammunition just days before oral argument. At the same time, FDA is escalating its…
-
17% Weight Loss in 16 Weeks… Is This Better Than Retatrutide?
September 15, 2026 · 30 minLilly just gave us a glimpse of what could come after today’s GLP-1s, and it may not be about simply pushing patients to stronger drugs and higher doses. This week on On The Pen: The Weekly Dose, we break down Lilly’s surprising early…
Show 7 more episodesShow fewer episodes
-
GLP-1 for 6 Year Olds? Here’s What the Trial Actually Found
September 8, 2026 · 26 minIs obesity still a disease worthy of treatment when the patient is six years old? This week, Novo Nordisk released Phase 3 STEP Young data in children ages 6 to 11 with obesity. After 68 weeks, 40.4% of children treated with semaglutide…
-
We’re Solving Obesity. Now Who Pays for It?
September 2, 2026 · 25 minThis week on On The Pen, the GLP-1 story is moving in two very different directions. The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its consumer guidance around compounded GLP-1…
-
GLP-1 Coverage Is COLLAPSING in 2027
August 26, 2026 · 35 minGLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health. In this episode of the On The Pen Podcast, Dave Knapp breaks down two of the biggest GLP-1 stories…
-
$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”
August 18, 2026 · 45 minCould GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America. But getting there may depend on something…
-
200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study
August 12, 2026 · 31 minHttps://www.otplinks.com Based on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so these are estimated from speaking pace and topic position. A GLP-1…
-
Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.
August 4, 2026 · 19 minNovo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes increasingly important, Novo may be…
About the show
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 0.5% of all podcasts globally, and On The Pen is a top Substack best-seller.